Equities

Medpace Holdings Inc

Medpace Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)347.82
  • Today's Change6.00 / 1.76%
  • Shares traded78.89k
  • 1 Year change+25.63%
  • Beta1.3725
Data delayed at least 15 minutes, as of Nov 22 2024 15:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform3
Hold6
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Medpace Holdings Inc have a median target of 349.00, with a high estimate of 404.00 and a low estimate of 305.00. The median estimate represents a 2.10% increase from the last price of 341.82.
High18.2%404.00
Med2.1%349.00
Low-10.8%305.00

Earnings history & estimates in USD

On Oct 21, 2024, Medpace Holdings Inc reported 3rd quarter 2024 earnings of 3.01 per share. This result exceeded the 2.78 consensus of the 8 analysts covering the company and exceeded last year's 3rd quarter results by 35.59%.
The next earnings announcement is expected on Feb 10, 2025.
Average growth rate+9.07%
Medpace Holdings Inc reported annual 2023 earnings of 8.88 per share on Feb 12, 2024.
Average growth rate+31.44%
More ▼

Revenue history & estimates in USD

Medpace Holdings, Inc. had 3rd quarter 2024 revenues of 533.32m. This missed the 540.99m consensus estimate of the 8 analysts following the company. This was 22.86% above the prior year's 3rd quarter results.
Average growth rate+2.02%
Medpace Holdings, Inc. had revenues for the full year 2023 of 1.89bn. This was 29.17% above the prior year's results.
Average growth rate+21.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.